Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic merkel cell carcinoma

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages

  Davids, Matthew ^a   Charlton, Amanda ^a   Ng, Swee Siang ^a   Chong, Mei Ling ^a   Laubscher, Kevin ^b   Dar, Mohammed ^b   Hodge, Jeffrey ^b   Soong, Richie ^a   Goh, Boon Cher ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; OXONIC ACID; PACLITAXEL; PAZOPANIB; TEGAFUR; BIOLOGICAL MARKER; CAM 5.2 ANTIGEN; ENOLASE; KERATIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

AGED; ARTICLE; ASPIRATION BIOPSY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXCISION; FEMALE; GALLSTONE; GASTROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE; MAMMOGRAPHY; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NECK TUMOR; PANCREATITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIATION NECROSIS; SKIN BIOPSY; SKIN GRAFT; SKIN METASTASIS; SKIN SWELLING; SKULL; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; FATALITY; GENETICS; METABOLISM; METASTASIS; MUTATION; NUCLEOTIDE SEQUENCE; SCALP; SKIN TUMOR;

AGED; BASE SEQUENCE; BIOLOGICAL MARKERS; CARCINOMA, MERKEL CELL; DNA MUTATIONAL ANALYSIS; FATAL OUTCOME; FEMALE; HUMANS; KERATINS; MUTATION; NEOPLASM METASTASIS; PHOSPHOPYRUVATE HYDRATASE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SCALP; SKIN NEOPLASMS; SULFONAMIDES;

EID: 70349331507     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.21.8149     Document Type: Article

References (12)

1. Allen PJ, Brown WB, Jaques DP, et al: Merkel cell carcinoma: Prognosis and treatment of patients from a single institution. J Clin Oncol 23:2300-2309, 2005
2. Eng TY, Boersma MG, Fuller CD, et al: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol 30:624-636, 2007
3. Garneski KM, Nghiem P: Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapy. J Am Acad Dermatol 57:166-169, 2007
4. Voog E, Biron P, Martin JP, et al: Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85:2589-2595, 1999
5. Sonpavde G, Hutson TE: Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 9:115-119, 2007
6. Kartha RV, Sundram UN: Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: Implications for tyrosine kinase-based tumorigenesis. Mod Pathol 21:96-104, 2008
7. Houben R, Michel B, Vetter-Kauczok CS, et al: Absence of classical MAP kinase pathway signaling in Merkel cell carcinoma. J Invest Dermatol 126:1135-1142, 2006
8. Kondapalli L, Soltani K, Lacouture ME: The promise of molecular target therapies: Protein kinase inhibitors in the treatment of cutaneous malignancies. J Am Acad Dermatol 53:291-302, 2005
9. Fernandez-Figueras MT, Puig L, Musulen E, et al: Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod Pathol 20:90-101, 2007
10. Kukko H, Koljonen V, Lassus P, et al: Expression of vascular endothelial growth factor receptor-2 in Merkel cell carcinoma. Anticancer Res 27:2587-2589, 2007
11. Feinmesser M, Halpern M, Kaganovsky E, et al: C-kit expression in primary and metastatic Merkel cell carcinoma. Am J Dermatopathol 26:458-462, 2004
12. Swick BL, Ravdel L, Fitzpatrick JE, et al: Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: Implications for treatment with imatinib mesylate. J Cutan Pathol 35:197-202, 2008